Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a one in a million. No really, that’s the incidence. Even though it’s rare, it’s worth reading this updated review since our treatments make it so easy to cure (or if you’re a glass half-empty kinda guy, so easy to cause late toxicities). Usually all it needs is low-dose radiation +/- a couple of cycles of ABVD. Importantly, unlike all other HL, they express CD20--but not CD30--so CD20-targeted therapies are a good salvage option. Recognize NLPHL when you see it because its one of the rare cancers on which you might wanna take it easy at first.